Attached files
| file | filename |
|---|---|
| 10-Q - 10-Q - Aptalis Pharma Inc | m70832e10vq.htm |
| EX-3.1 - EX-3.1 - Aptalis Pharma Inc | m70832exv3w1.htm |
| EX-31.2 - EX-31.2 - Aptalis Pharma Inc | m70832exv31w2.htm |
| EX-32.2 - EX-32.2 - Aptalis Pharma Inc | m70832exv32w2.htm |
| EX-31.1 - EX-31.1 - Aptalis Pharma Inc | m70832exv31w1.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Aptalis Pharma Inc. (the “Company”) for
the period ending March 31, 2011 as filed with the Securities and Exchange Commission on the
date hereof (the “Report”), I, Frank Verwiel, M.D., President and Chief Executive Officer of the
Company, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to section 906 of the
Sarbanes-Oxley Act of 2002, that:
| 1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and | ||
| 2) | The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
A signed original of this written statement has been provided to the Company and will be
retained by the Company and furnished to the SEC or its staff upon request.
Date: May 13, 2011
| /s/ Frank Verwiel, M.D. | ||||
| Frank Verwiel, M.D. | ||||
| President and Chief Executive Officer (Principal Executive Officer) |
||||